

Edgar Filing: QUEST DIAGNOSTICS INC - Form SC 13D/A

QUEST DIAGNOSTICS INC  
Form SC 13D/A  
May 22, 2002

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

SCHEDULE 13D  
(Amendment No. 2)

UNDER THE SECURITIES EXCHANGE ACT OF 1934  
Quest Diagnostics Incorporated

-----  
(Name of Issuer)

Common Stock, par value \$0.01 per share

-----  
(Title of Class of Securities)

74834L 10 0

-----  
(CUSIP Number)

Donald F. Parman, GlaxoSmithKline  
One Franklin Plaza, Philadelphia, PA 19102  
Telephone 215-751-7633

-----  
(Name, Address and Telephone Number of Person Authorized to  
Receive Notices and Communications)

May 21, 2002

-----  
(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(b) (3) or (4), check the following box / /.

Check the following box if a fee is being paid with the statement / /. (A fee is not required only if the reporting person: (1) has a previous statement on file reporting beneficial ownership of more than five percent of the class of securities described in Item 1; and (2) has filed no amendment subsequent thereto reporting beneficial ownership of five percent or less of such class.) (See Rule 13d-7.)

Note: Six copies of this statement, including all exhibits, should be filed with the Commission. See Rule 13d-1(a) for other parties to whom copies are to be sent.

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and

for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Edgar Filing: QUEST DIAGNOSTICS INC - Form SC 13D/A

This Amendment No. 2 amends and supplements the Statement on Schedule 13D electronically filed with the Securities and Exchange Commission (the "Commission") on August 19, 1999, and an amendment electronically filed with the Commission on May 11, 2001.

The undersigned hereby amends and supplements Items 2, 5, 6 and 7 of the Schedule 13D as previously amended to include the following information (capitalized terms used herein without definition shall have the same meaning as set forth in the Schedule 13D as previously amended).

SCHEDULE 13D

CUSIP NO. 74834L 10 0

1 NAME OF REPORTING PERSON  
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

GlaxoSmithKline plc

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP\*

(a) / /  
(b) / /

3 SEC USE ONLY

4 SOURCE OF FUNDS\*

OO

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E)

/ /

6 CITIZENSHIP OR PLACE OF ORGANIZATION

England and Wales

7 SOLE VOTING POWER  
NUMBER OF  
SHARES 22,128,672

8 SHARED VOTING POWER  
BENEFICIALLY OWNED BY EACH REPORTING PERSON

9 SOLE DISPOSITIVE POWER  
WITH

22,128,672

10 SHARED DISPOSITIVE POWER

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

22,128,672

Edgar Filing: QUEST DIAGNOSTICS INC - Form SC 13D/A

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES  
CERTAIN SHARES\*

/ /

-----  
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

22.8%

-----  
14 TYPE OF REPORTING PERSON\*

CO

-----  
\*SEE INSTRUCTIONS BEFORE FILLING OUT!

Item 1. Security and Issuer.

Item 2. Identity and Background.

(b) The address of the Company's principal executive office is GlaxoSmithKline House, 980 Great West Road, Brentford, Middlesex TW8 9GS, England.

(c) Set forth in Schedule I to this Amendment ("Schedule I") are the names, business address and present principal occupation or employment of each executive officer and director of the Company.

(d) During the last five years, there have been no criminal proceedings against the Company or, to the best knowledge of the Company, any of the other persons with respect to whom information is given in response to this Item 2.

(e) During the last five years, neither the Company nor, to the best knowledge of the Company, any of the other persons with respect to whom information is given in response to this Item 2 has been a party to any civil

proceeding of a judicial or administrative body of competent jurisdiction resulting in a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or State securities laws or finding any violation with respect to such laws.

(f) The citizenship of each executive officer and director of the Company is set forth in Schedule I.

Item 3. Source and Amount of Funds or Other Consideration.

Item 4. Purpose of Transaction.

Item 5. Interest in Securities of the Issuer.

(a) Amount and Percent Beneficially Owned

The Company beneficially owns 22,128,672 shares of Common Stock. The number of shares of Common Stock beneficially owned by the Company represents 22.8% of the 95,005,940 shares of Common Stock outstanding at April 30, 2002. Those shares are held by SmithKline Beecham Corporation ("SKB"), a wholly-owned subsidiary of the Company. The directors and executive officers of the Company disclaim beneficial ownership of these shares.

(c) Subsequent to Amendment No. 1, SKB received 11,064,336 shares

## Edgar Filing: QUEST DIAGNOSTICS INC - Form SC 13D/A

pursuant to a two-for-one stock split effective May 31, 2001.

Item 6. Contracts, Arrangements, Understandings or  
Relationship With respect to Securities of the Issuer.

On May 21, 2002, SKB entered into an ISDA Master Agreement (including the Schedule and Credit Support Annex thereto) (the "ISDA Master Agreement") with Lehman Brothers Finance S.A. ("Lehman"). On May 21, 2002, SKB and Lehman also entered into 5 transactions (each, a "Transaction") governed by the ISDA Master Agreement (the confirmations evidencing the Transactions, along with the ISDA Master Agreement, the "Agreement") relating to a total of 5,000,000 Shares. SKB has agreed to sell to Lehman, for settlement ranging from July 13, 2006 to March 27, 2008, a number of Shares to be determined based on a formula, which has been structured to provide SKB a hedge against depreciation in the value of the Shares while participating in a portion of the upside of the Shares. SKB has the right to cash settle the Transactions by paying an amount in cash equal to the value of the Shares it would otherwise be obligated to deliver.

The number of Shares to be delivered will be determined based on a formula as follows. If the price of the Shares determined near the settlement date of a Transaction (the "Final Price") is at or below a specified Depreciation Floor (\$84.55 as defined in each Transaction), SKB will be obligated to deliver all the Shares underlying that particular Transaction. If the Final Price is above the

specified Depreciation Floor and at or below a specified Appreciation Cap (ranging from \$106.11 to \$125.30 as defined in each relevant Transaction), SKB will be obligated to deliver a number of Shares equal to the number of Shares underlying that particular Transaction multiplied by the Depreciation Floor divided by the Final Price. If the Final Price is above the specified Appreciation Cap, SKB will be obligated to deliver a number of Shares equal to the number of Shares underlying that particular Transaction multiplied by (i) 1.0 minus (ii) (a) the Appreciation Cap minus the Depreciation Floor divided by (b) the Final Price.

Under the Agreement, SKB has pledged to Lehman 5,000,000 Shares. Absent default or SKB's consent, Lehman is not entitled to dispose of nor vote the pledged Shares. In addition, SKB has the right to substitute other collateral.

Item 7. Materials to be Filed as Exhibits.

Item 7 is amended by adding the following exhibits thereto.

Exhibit number	Description
4	ISDA Master Agreement between SmithKline Beecham Corporation and Lehman Brothers Finance S.A. dated May 21, 2002
5	Confirmation between SmithKline Beecham Corporation and Lehman Brothers Finance S.A. dated May 21, 2002 with Averaging Dates (as defined in this Confirmation) from May 8, 2007 through May 21, 2007
6	Confirmation between SmithKline Beecham Corporation and Lehman Brothers Finance S.A. dated May 21, 2002 with Averaging Dates (as defined in this Confirmation) from March 10, 2008 through March 24, 2008

Edgar Filing: QUEST DIAGNOSTICS INC - Form SC 13D/A

- 7 Confirmation between SmithKline Beecham Corporation and Lehman Brothers Finance S.A. dated May 21, 2002 with Averaging Dates (as defined in this Confirmation) from July 10, 2006 through July 21, 2006
- 8 Confirmation between SmithKline Beecham Corporation and Lehman Brothers Finance S.A. dated May 21, 2002 with Averaging Dates (as defined in this Confirmation) from December 8, 2006 through December 21, 2006
- 9 Confirmation between SmithKline Beecham Corporation and Lehman Brothers Finance S.A. dated May 21, 2002 with Averaging Dates (as defined in this Confirmation) from October 9, 2007 through October 22, 2007

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in the Statement is true, correct and complete.

DATED: May 22, 2002

GLAXOSMITHKLINE PLC

By: /s/ Donald F. Parman

-----  
DONALD F. PARMAN  
Authorized Representative

SCHEDULE I

Name	Business Address	Principal Occupation or Employment	Nati
BOARD OF DIRECTORS			
Sir Francis Roger Hurn	Marconi plc One Bruton Street London, England W1X 8AQ	Company Director	Brit
Dr. Jean-Pierre Garnier	One Franklin Plaza Philadelphia, PA 19102	Chief Executive Officer	Fren
John D. Coombe	GlaxoSmithKline House 980 Great West Road Brentford, Middlesex England TW8 9GS	Chief Financial Officer	Brit
Paul Allaire	PO Box 1600 Stamford, CT 06904	Company Director	USA
Dr. Michele Barzach	Sante International 2 Rue Cognac-Jay Paris, France	Health Strategy Consultant	Fren

Edgar Filing: QUEST DIAGNOSTICS INC - Form SC 13D/A

75007

Sir Christopher Hogg	Reuters Holdings plc 85 Fleet Street London, England EC4P 4AJ	Company Director	Brit
Sir Peter Job	Reuters Holdings plc 85 Fleet Street London, England EC4P 2DB	Company Director	Brit
John McArthur	140 Old Connecticut Path Wayland, MA 01778	Company Director	Canad
Donald McHenry	IRC Group 1320 19TH Street NW Suite 410 Washington, DC 20036	Company Director	USA
Sir Ian Prosser	20 North Audley Street London, England W1Y 1WE	Company Director	Brit
Dr. Ronaldo Schmitz	34 Berkeley Square London, England W1J 5AA	Company Director	Germ
Dr. Lucy Shapiro	Stanford Univerity School of Medicine 279 Campus Drive Stanford, CA 94305-5329	Professor	USA
COMPANY SECRETARY			
Simon M. Bicknell	GlaxoSmithKline House 980 Great West Road Brentford, Middlesex England TW8 9GS	Company Secretary	Brit
CORPORATE EXECUTIVE TEAM			
Jean-Pierre Garnier	One Franklin Plaza Philadelphia, PA Officer 19102	Chief Executive	Fren
Rupert M. Bondy	GlaxoSmithKline House 980 Great West Road Brentford, Middlesex England TW8 9GS	Senior Vice President and General Counsel	Brit
W. Ford Calhoun	One Franklin Plaza Philadelphia, PA	Senior Vice President Information Technology	USA

Edgar Filing: QUEST DIAGNOSTICS INC - Form SC 13D/A

19102

John D. Coombe	GlaxoSmithKline House 980 Great West Road Brentford, Middlesex England TW8 9GS	Chief Financial Officer	Brit
Robert A. Ingram	5 Moore Drive Research Triangle Park NC 27709	Chief Operating Officer & President Pharmaceutical Operations	USA
Dr. James B. Palmer	5 Moore Drive Research Triangle Park NC 27709	Senior Vice President New Product Development Pharmaceuticals R&D	Brit
Daniel J. Phelan	One Franklin Plaza Philadelphia, PA 19102	Senior Vice President Human Resources	USA
Howard Pien	One Franklin Plaza Philadelphia, PA 19102	President Pharmaceuticals International	USA
David M. Stout	5 Moore Drive Research Triangle Park NC 27709	President U.S. Pharmaceuticals	USA
Tim Tyson	5 Moore Drive Research Triangle Park NC 27709	President Global Manufacturing & Supply	USA
Christopher Viehbacher	100 rue de Versailles 78163 Marly-Le-Roi Cedex, France Europe	President Pharmaceuticals	Germ Can
Dr. Tadataka Yamada	709 Swedeland Road King of Prussia, PA 19406	Chairman Research & Development	USA
Jennie Younger	GlaxoSmithKline House 980 Great West Road Brentford, Middlesex England TW8 9GS	Senior Vice President Corporate Communications & Community Partnerships	Brit
Jack Ziegler	One Franklin Plaza Philadelphia, PA 19102	President Consumer Healthcare	USA